2023 World Conference on Lung Cancer (Posters)-EP06.06. Expression of miR-30a-5p in Expression of Mir-30A-5P in Extracellular Vesicle as a Prognostic Biomarker for Non Small Cell Lung Cancer Therapy

EP06.06. Expression of miR-30a-5p in Expression of Mir-30A-5P in Extracellular Vesicle as a Prognostic Biomarker for Non Small Cell Lung Cancer Therapy - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the expression of miR-30a-5p in extracellular vesicles as a prognostic biomarker for non-small cell lung cancer (NSCLC) therapy. The researchers collected peripheral blood samples from 16 NSCLC patients before and after therapy and measured the levels of miR-30a-5p using quantitative real-time PCR. They found that the relative expression of miR-30a-5p decreased after therapy in patients with partial response and stable disease, and increased in patients with progressive disease. The median overall survival was 39.6 weeks, and the median progression-free survival (PFS) was 38.5 weeks. PFS was not found to be correlated with miR-30a-5p expression. However, a high miR-30a-5p relative expression change was significantly associated with a shorter PFS duration. The ROC curve analysis showed an area under the curve of 0.854. <br /><br />The researchers concluded that miR-30a-5p is a potential minimally invasive biomarker for monitoring lung cancer therapy outcomes. They found that miR-30a-5p expression was inversely related to PFS duration in NSCLC patients. This study highlights the potential of miR-30a-5p as a prognostic biomarker for NSCLC therapy and suggests that monitoring its expression could help predict treatment outcomes.

Asset Subtitle

Mariska Pangaribuan

Meta Tag

Speaker Mariska Pangaribuan

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

miR-30a-5p

extracellular vesicles

prognostic biomarker

non-small cell lung cancer

NSCLC therapy

peripheral blood samples

quantitative real-time PCR

partial response

stable disease

progressive disease